

Apple Health PDL Drug Class Motions

Antihyperlipidemics

- ▶ Adenosine Triphosphate-Citrate Lyase Inhibitors
- ▶ Angiotensin-Like Protein Inhibitors
- ▶ Microsomal Triglyceride Transfer Protein (MTP) Inhibitor
- ▶ PCSK-9 Inhibitors

Antihyperlipidemics

Motion: I move that all products in the drug classes listed on slide 2 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Beste**
- ▶ **2nd: Barkett**

Substance Use Disorder

- ▶ Agents For Opioid Withdrawal
- ▶ Opioid Antagonists
- ▶ Opioid Partial Agonists - Subcutaneous
- ▶ Opioid Partial Agonists - Transmucosal

Substance Use Disorder

Motion: I move that all products in the drug classes listed on slide 4 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Taylor**
- ▶ **2nd: Hudson**

Movement Disorder Agents

- ▶ **Motion:** I move that all products in the Movement Disorder Agents class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Chawla**
- ▶ **2nd: Barkett**

Oncology Agents

- ▶ ANTIBODIES - INJECTABLE
- ▶ Gamma Secretase Inhibitors
- ▶ HIF-2-Alpha Inhibitors
- ▶ KRAS Inhibitors
- ▶ Ornithing Decarboxylase Inhibitors

Oncology Agents

Motion: I move that all products in the drug classes listed on slide 7 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Corsilles**
- ▶ **2nd: Beste**

Endocrine and Metabolic Agents

- ▶ NH3 Inhibitors
- ▶ Parathyroid Hormones

Endocrine and Metabolic Agents

Motion: I move that all products in the drug classes listed on slide 9 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Beste**
- ▶ **2nd: Barkett**

Hematopoietic Agents : CXCR4 Receptor Antagonists

- ▶ **Motion:** I move that all products in the Hematopoietic Agents : CXCR4 Receptor Antagonists class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Chawla**
- ▶ **2nd: MacKay**

Pulmonary Hypertension Agents

- ▶ Activin Signaling Inhibitor
- ▶ Combinations

Pulmonary Hypertension Agents

Motion: I move that all products in the drug classes listed on slide 12 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Barkett**
- ▶ **2nd: Taylor**

AHDPL Classes

▶ Antifungals

- ▶ Topical

▶ Antivirals

- ▶ Influenza Agents
- ▶ Smallpox Agents

▶ Cardiovascular Agents

- ▶ Sinus Node Inhibitors
- ▶ Transthyretin Stabilizers
- ▶ Vasoactive Soluble Guanylate Cylcase Stimulators (SGC)

AHDPL Classes

▶ Endocrine And Metabolic Agents

- ▶ Fabry Disease Agents – Injectable
- ▶ Fabry Disease Agents – Oral
- ▶ Fatty Acid Metabolism Agents
- ▶ Pituitary Suppressants

▶ Gastrointestinal Agents

- ▶ Inflammatory Bowel Agents
- ▶ Irritable Bowel Syndrome (IBS) Agents / Gi Motility

▶ Genitourinary Agents

- ▶ Overactive Bladder Agents

AHDPL Classes

- ▶ Hematological Agents
 - ▶ Hereditary Angioedema Agents
- ▶ Multiple Sclerosis Agents :
- ▶ Neuromuscular Agents
 - ▶ Freidrichs Ataxia Agents
 - ▶ Rett Syndrome Agents
- ▶ Oncology Agents
 - ▶ Allogenic Cellular Immunotherapy
 - ▶ Gonadotropin-Releasing Hormone (GNRH) Receptor Antagonists – Oral

AHDPL Classes

- ▶ Oncology Agents (Cont.)
 - ▶ Interferons
 - ▶ LHRH Analogs – Injectable
 - ▶ Urinary Tract Protective Rescue Agents - Oral
- ▶ Ophthalmic Agents
 - ▶ Cholinergic Agonists
 - ▶ Complement Inhibitors
- ▶ Vitamins
 - ▶ Vitamin D / Vitamin D Analogs – Oral

AHPDL Classes

Motion: I move that all products in the drug classes listed on slides 14, 15, 16, and 17 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

▶ **GENITOURINARY AGENTS : OVERACTIVE BLADDER AGENTS**

- ▶ At least one once daily formulation must be included as a preferred drug on the AHPDL.
- ▶ At least one agent that is not associated with adverse cognitive outcomes must be included as a preferred drug on the AHPDL.

▶ **Motion: MacKay**

▶ **2nd: Corsilles**